{"id":"W4225678126","doi":"10.1093/ehjcvp/pvac023","title":"Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial","year":2022,"lang":"en","type":"article","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; McMaster University; Population Health Research Institute; Hamilton Health Sciences; Hamilton General Hospital","funders":"Janssen Pharmaceuticals; Idorsia Pharmaceuticals; KU Leuven; Sanofi; Bayer HealthCare; Bristol-Myers Squibb; CSL Behring; Merck; Bayer; Servier; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Rivaroxaban; Aspirin; Coronary artery disease; Internal medicine; Myocardial infarction; Stroke (engine); Randomized controlled trial; Hazard ratio; Confidence interval; Warfarin; Surgery; Cardiology; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005209692,0.000893575,0.001532154,0.0003153049,0.0004204255,0.001561874,0.0005741176,0.001276844,0.001272616],"category_scores_gemma":[0.004106636,0.0003327638,0.001770654,0.0006647327,0.0006788665,0.001121301,0.0008552945,0.001516494,0.0002242679],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000678971,"about_ca_system_score_gemma":0.001108279,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001269921,"about_ca_topic_score_gemma":0.002332506,"domain_scores_codex":[0.9975436,0.001514796,0.0001864766,0.0003125494,0.0002301636,0.0002122875],"domain_scores_gemma":[0.9950185,0.0006666783,0.002419509,0.0004111618,0.0003468915,0.001137137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7444111,0.004402522,0.2177606,0.0007190114,0.007490599,0.000181513,0.0002424178,0.0007353747,0.001833475,0.0001910188,0.002090332,0.01994205],"study_design_scores_gemma":[0.3004984,0.09770152,0.5844844,0.0003634793,0.007842614,0.0005861131,0.0003157637,0.001807722,0.0010542,0.0004203143,0.004800994,0.0001244838],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944385,0.003011117,0.0001561991,0.0003153526,0.00009349833,0.0002256584,0.001050579,0.00001210021,0.0006969221],"genre_scores_gemma":[0.9938175,0.001072448,0.0003934189,0.000504271,0.0004501886,0.000416642,0.002911028,0.000005959453,0.0004285204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005209692,"threshold_uncertainty_score":0.02755183,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06342639653316291,"score_gpt":0.3316879162528724,"score_spread":0.2682615197197095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}